: Phase Ib

Sarawak reported data from two Phase Ib studies of (+)-calanolide A monotherapy in a total of 43 treatment-naïve HIV positive patients in the U.S., Malaysia and Singapore. Following 14 days of treatment and a subsequent 14 days of follow-up, a 600 mg twice daily dose of the product produced a 0.81 log reduction in viral load from baseline (p=0.0016 versus baseline and p=0.027 versus placebo). Resistance to the compound was not observed, Sarawak said. Data were presented at the Retroviruses and Opportunistic Infections conference in San Francisco. ...